Disease relevance of Eosinophilia-Myalgia Syndrome

• L-tryptophan-associated eosinophilic fasciitis prior to the 1989 eosinophilia-myalgia syndrome outbreak [1].
• Pulmonary hypertension in a patient with tryptophan-induced eosinophilia-myalgia syndrome [2].
• BACKGROUND: The eosinophilia-myalgia syndrome, caused by a contaminant or contaminants in epidemiologically implicated L-tryptophan products, is characterized by eosinophilia and eosinophil degranulation [3].
• Peripheral neuropathy in the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion [4].
• Mononeuropathy multiplex in tryptophan-associated eosinophilia-myalgia syndrome [5].

High impact information on Eosinophilia-Myalgia Syndrome

• Tryptophan-induced eosinophilia-myalgia syndrome [6].
• To investigate the metabolism of L-tryptophan (LT) via the kynurenine pathway in patients with the eosinophilia-myalgia syndrome (EMS) [7].
• Tryptophan metabolism via the kynurenine pathway in patients with the eosinophilia-myalgia syndrome [7].
• Interleukin-4 levels in the eosinophilia-myalgia syndrome [8].
• Eosinophilia, brawny induration, and tenderness of the skin and deeper tissues, and eosinophilic and lymphocytic infiltration of skin, deep fascia, and muscle characterize the acute eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan [4].

Chemical compound and disease context of Eosinophilia-Myalgia Syndrome

• 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome [9]?
• Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome [10].
• Commercially available melatonin was found to contain impurities associated with eosinophilia-myalgia syndrome (EMS) [11].
• The eosinophilia-myalgia syndrome: the Los Alamos Conference [12].
• Studies with 1,1'-ethylidenebis(tryptophan), a contaminant associated with L-tryptophan implicated in the eosinophilia-myalgia syndrome [13].

Biological context of Eosinophilia-Myalgia Syndrome

• To describe the epidemiology of the eosinophilia-myalgia syndrome further and elucidate a possible association with the manufacturing process, we conducted surveillance for the syndrome in Minnesota, a community survey of tryptophan use in Minneapolis-St [14].
• 31 patients with L-tryptophan-associated eosinophilia-myalgia syndrome (EMS) that developed during the United States outbreak in 1989 were followed up prospectively at a university hospital outpatient rheumatology clinic for 16 to 24 months from the onset of their illness [15].
• The recent recognition of the eosinophilia-myalgia syndrome (EMS) associated with the ingestion of L-tryptophan prompted an analysis of the peripheral blood eosinophil phenotypes and of the serum eosinophil hematopoietins in this disorder [16].
• Epidemic eosinophilia-myalgia syndrome (EMS) associated with excess L-tryptophan (Trp) consumption in humans has been declared a major public health problem [17].

Anatomical context of Eosinophilia-Myalgia Syndrome

• Immune-mediated mechanisms and immune activation of fibroblasts in the pathogenesis of eosinophilia-myalgia syndrome induced by L-tryptophan [18].
• A newly recognized and well-described connective tissue disease, eosinophilia-myalgia syndrome, is thought to relate to L-tryptophan ingestion [19].
• We have determined that the addition of 3-phenylamino-L-alanine (PAA), a recently reported contaminant in L-tryptophan implicated in the eosinophilia-myalgia syndrome, affects tryptophan binding by utilizing an in vitro measurement of 3H-tryptophan binding to hepatic nuclei or nuclear envelopes [20].

Gene context of Eosinophilia-Myalgia Syndrome

• While the pathogenesis of eosinophilia-myalgia syndrome (EMS) remains obscure, the ingestion of L-trypophan (LT) and possibly certain constituents in the LT product might be associated [21].
• Restrictive cardiomyopathy associated with the eosinophilia-myalgia syndrome [22].
• OBJECTIVE: We report the first case of restrictive cardiomyopathy occurring in a patient with the eosinophilia-myalgia syndrome [22].
• Autoantibodies in sera from patients with L-tryptophan-associated eosinophilia-myalgia syndrome. Demonstration of unique antigen-antibody specificities [23].
• PMS and eosinophilia-myalgia syndrome [24].

Analytical, diagnostic and therapeutic context of Eosinophilia-Myalgia Syndrome

• Epidemiologic studies strongly associate eosinophilia-myalgia syndrome (EMS) with ingestion of tryptophan containing a contaminant ("peak E") [25].
• To identify chemical contaminant(s) associated with eosinophilia-myalgia syndrome (EMS), case and control lots of tryptophan were analyzed by HPLC with both UV and FL detection [26].

References